Compare Abbott Laboratories (ABT) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Clorox Co — how do they compare? Abbott Laboratories trades at $108.75 (market cap $187.95B), while Clorox Co trades at $106.19 (market cap $13.09B). The key difference: Abbott Laboratories is far larger — about 14.4× Clorox Co's market cap, and Clorox Co pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| ABT | CLX | |
|---|---|---|
Market Cap | $187.95B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $127.16 |
52-Week Low | $82.57 | $86.12 |
Enterprise Value | $214.96B | $18.47B |
Dividend Yield | 2.32% | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Clorox (CLX) trades at $107.70, up 2.43% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations, though Q4 2025 missed. The company maintains solid profitability with a net margin of 8.74% and ROE of 285.64%, but faces high P/B of 145.45. News highlights Q4 sales beat and a dividend increase to $1.25 per share, while inflation and consumer value-seeking pose challenges.
Outlook is mixed: improving market share and strategic initiatives support growth, but inflation and competitive pressures risk margins. Analyst consensus is cautious with a hold-heavy rating and $97.50 price target below current levels. Key risks include supply-chain inflation and weak organic sales, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
